Uroplakin III-Delta4 Messenger RNA as a Promising Marker to Identify Nonulcerative Interstitial Cystitis

Zeng, Yu; Wu, Xiu-Xian; Homma, Yukio; Yoshimura, Naoki; Iwaki, Hideaki; Kageyama, Susumu; Tokura, Y.; Kakehi, Yoshiyuki

doi:10.1016/j.juro.2007.05.125

Cited by 40 publications

(30 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial attempts to develop a urinary biomarker concentrated on mediators of pain such as substance P (18). Other proposed pain biomarkers have included uroplakin III-δ4 mRNA (19), and heparin-binding epidermal growth factor-like growth factor (HB-EGF) (20). Antiproliferative factor (APF) is another candidate (21).…”

Section: Commentsmentioning

confidence: 99%

Urinary proteomics evaluation in interstitial cystitis/painful bladder syndrome: a pilot study

et al. 2010

View full text Add to dashboard Cite

Purpose: Interstitial cystitis/painful bladder syndrome (IC/PBS) is characterized by chronic pain, pressure and discomfort felt in the pelvis or bladder. An in-depth shotgun proteomics study was carried out to profile the urinary proteome of women with IC/PBS to identify possible specific proteins and networks associated with IC/PBS. Materials and Methods: Urine samples from ten female IC/PBS patients and ten female asymptomatic, healthy control subjects were analyzed in quadruplicate by liquid chromatography-tandem mass spectrometry (LC-MS/MS) on a hybrid linear ion trap-orbitrap mass spectrometer. Gas-phase fractionation (GPF) was used to enhance protein identification. Differences in protein quantity were determined by peptide spectral counting. Results: α-1B-glycoprotein (A1BG) and orosomucoid-1 (ORM1) were detected in all IC/PBS patients, and ≥ 60% of these patients had elevated expression of these two proteins compared to control subjects. Transthyretin (TTR) and hemopexin (HPX) were detected in all control individuals, but ≥ 60% of the IC/PBS patients had decreased expression levels of these two proteins. Enrichment functional analysis showed cell adhesion and response to stimuli were down-regulated whereas response to inflammation, wounding, and tissue degradation were up-regulated in IC/PBS. Activation of neurophysiological processes in synaptic inhibition, and lack of DNA damage repair may also be key components of IC/PBS. Conclusion: There are qualitative and quantitative differences between the urinary proteomes of women with and without IC/PBS. We identified a number of proteins as well as pathways/networks that might contribute to the pathology of IC/PBS or result from perturbations induced by this condition.

show abstract

Section: Commentsmentioning

confidence: 99%

Urinary proteomics evaluation in interstitial cystitis/painful bladder syndrome: a pilot study

et al. 2010

View full text Add to dashboard Cite

show abstract

“…39 Uroplakin III Bladder Over expression of uroplakin III-delta4 was found in bladders of patients with non-ulcerative type BPS/IC. 38 APF Urine APF altered the pattern of cellular gene expression toward a phenotype similar to that of cells from BPS/IC bladders. 37,[41][42][43][44]50,51 APF Urine APF activities decrease significantly after hydrodistention.…”

Section: Chronic Inflammation In Oab and Bps/icmentioning

confidence: 99%

“…37 In addition, overexpression of uroplakin III-delta4 was found in bladders of patients with non-ulcerative type BPS/IC, which might be a potential biomarker for identifying patients with BPS/IC. 38 Abnormal expression of differentiation related proteins (keratin 18 and 20) and proteoglycan core proteins (biglycan, decorin, perlecan and syndecan-1), which are found in BPS/IC bladders, also suggest a loss of barrier function proteins, and altered differentiation proteins are independent and occur independently of inflammation. 39 BUC in BPS/IC patients produce a unique APF, which is secreted into the urine of BPS/IC patients, whereas normal BUC do not; this APF inhibited proliferation of cultured BUC.…”

Section: Urothelial Differentiation Proteins and Proteoglycan Proteinmentioning

confidence: 99%

Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis

Kuo

2014

Int J of Urology

View full text Add to dashboard Cite

Abbreviations & Acronyms APF = antiproliferative factor BPS/IC = bladder pain syndrome/interstitial cystitis BUC = bladder urothelial cells CRP = C-reactive protein EGF = epidermal growth factor GP51 = glycoprotein 51 HB-EGF = heparin binding growth factor-like growth factor IC = interstitial cystitis IL = interleukin MCP-1 = monocyte chemotactic protein-1 MIP-1β = macrophage inflammatory protein OAB = overactive bladder NGF = nerve growth factor NIDDK = National Institute of Diabetes, Digestive, and Kidney Diseases TNF-α = tumor necrosis factor-α ZO-1 = zonula occludens-1 Abstract: There is a lack of consensus on the pathophysiology of bladder pain syndrome/ interstitial cystitis. The chronic pain symptoms of bladder pain syndrome/interstitial cystitis refractory to local treatment could be a result of central nervous system sensitization and persisting abnormalities in the bladder wall, which activate the afferent sensory system. Evidence also shows that bladder pain syndrome/interstitial cystitis is a heterogeneous syndrome and that the two subtypes, the ulcerative (classic) and non-ulcerative types, represent different disease entities. There is a need for non-invasive markers for the differential diagnoses of the subtypes of bladder pain syndrome/interstitial cystitis, and between bladder pain syndrome/interstitial cystitis and bladder sensory disorders, such as hypersensitive bladder syndrome or overactive bladder. Bladder pain syndrome/interstitial cystitis, but not overactive bladder, involves an aberrant differentiation program in the bladder urothelium that leads to altered synthesis of several proteoglycans, cell adhesion and tight junction proteins, and bacterial defense molecules. These findings have led to the rationale for identifying urinary biomarkers to detect bladder pain syndrome/interstitial cystitis in patients with frequency urgency syndrome. Recently, the markers that have been the focus of the most research are antiproliferative factor, epidermal growth factor, heparin-binding epidermal growth factor, glycosaminoglycans and bladder nitric oxide. In addition, inflammatory proteins in the urine and serum play important roles in the pathogenesis of bladder pain syndrome/interstitial cystitis. The urinary proteome is an easily accessible source of biomarkers for differentiation between inflammatory bladder disorders. Analysis of multiple urinary proteins and serum cytokines could provide a diagnostic basis for bladder pain syndrome/interstitial cystitis, and could be a tool for the differential diagnosis of bladder pain syndrome/interstitial cystitis and other sensory bladder disorders.

show abstract

“…Epithelial cell growth factors (185) GP51 (186) Uroplakin III-delta4 (187) biglycan, decorin, perlecan, Syndecan-1…”

Section: Chronic Periodontitismentioning

confidence: 99%

Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases

Prasad

Tyagi

Aggarwal

2016

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Inflammation is a part of the complex biological response of inflammatory cells to harmful stimuli, such as pathogens, irritants, or damaged cells. This inflammation has been linked to several chronic diseases including cancer, atherosclerosis, rheumatoid arthritis, and multiple sclerosis. Major biomarkers of inflammation include tumor necrosis factor, interleukins (IL)-1, IL-6, IL-8, chemokines, cyclooxygenase, 5-lipooxygenase, and C-reactive protein, all of which are regulated by the transcription factor nuclear factor-kappaB. Although examining inflammatory biomarkers in blood is a standard practice, its identification in saliva and/or urine is more convenient and non-invasive. In this review, we aim to (1) discuss the detection of these inflammatory biomarkers in urine and saliva; (2) advantages of using salivary and urinary inflammatory biomarkers over blood, while also weighing on the challenges and/or limitations of their use; (3) examine their role(s) in connection with diagnosis, prevention, treatment, and drug development for several chronic diseases with inflammatory consequences, including cancer; and (4) explore the use of innovative salivary and urine based biosensor strategies that may permit the testing of biomarkers quickly, reliably, and cost-effectively, in a decentralized setting.

show abstract

Uroplakin III-Delta4 Messenger RNA as a Promising Marker to Identify Nonulcerative Interstitial Cystitis

Abstract: Although the clinical implications of the over expression of uroplakin III and III-delta4 in nonulcerative interstitial cystitis bladders remains to be clarified, from the diagnostic viewpoint uroplakin III-delta4 is a potential marker for identifying nonulcerative interstitial cystitis.

Cited by 40 publications

References 19 publications

Urinary proteomics evaluation in interstitial cystitis/painful bladder syndrome: a pilot study

Urinary proteomics evaluation in interstitial cystitis/painful bladder syndrome: a pilot study

Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis

Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases

Contact Info

Product

Resources

About